222 related articles for article (PubMed ID: 28262675)
21. CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis.
Chung EY; Psathas JN; Yu D; Li Y; Weiss MJ; Thomas-Tikhonenko A
J Clin Invest; 2012 Jun; 122(6):2257-66. PubMed ID: 22546857
[TBL] [Abstract][Full Text] [Related]
22. IBTK Haploinsufficiency Affects the Tumor Microenvironment of Myc-Driven Lymphoma in E-myc Mice.
Vecchio E; Fiume G; Mignogna C; Iaccino E; Mimmi S; Maisano D; Trapasso F; Quinto I
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32019112
[TBL] [Abstract][Full Text] [Related]
23. AID and RAG1 do not contribute to lymphomagenesis in Emu c-myc transgenic mice.
Nepal RM; Zaheen A; Basit W; Li L; Berger SA; Martin A
Oncogene; 2008 Aug; 27(34):4752-6. PubMed ID: 18408759
[TBL] [Abstract][Full Text] [Related]
24. Deregulated expression of HDAC9 in B cells promotes development of lymphoproliferative disease and lymphoma in mice.
Gil VS; Bhagat G; Howell L; Zhang J; Kim CH; Stengel S; Vega F; Zelent A; Petrie K
Dis Model Mech; 2016 Dec; 9(12):1483-1495. PubMed ID: 27799148
[TBL] [Abstract][Full Text] [Related]
25. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants.
Hemann MT; Bric A; Teruya-Feldstein J; Herbst A; Nilsson JA; Cordon-Cardo C; Cleveland JL; Tansey WP; Lowe SW
Nature; 2005 Aug; 436(7052):807-11. PubMed ID: 16094360
[TBL] [Abstract][Full Text] [Related]
26. p19ARF is a critical mediator of both cellular senescence and an innate immune response associated with MYC inactivation in mouse model of acute leukemia.
Yetil A; Anchang B; Gouw AM; Adam SJ; Zabuawala T; Parameswaran R; van Riggelen J; Plevritis S; Felsher DW
Oncotarget; 2015 Feb; 6(6):3563-77. PubMed ID: 25784651
[TBL] [Abstract][Full Text] [Related]
27. Myc targets Cks1 to provoke the suppression of p27Kip1, proliferation and lymphomagenesis.
Keller UB; Old JB; Dorsey FC; Nilsson JA; Nilsson L; MacLean KH; Chung L; Yang C; Spruck C; Boyd K; Reed SI; Cleveland JL
EMBO J; 2007 May; 26(10):2562-74. PubMed ID: 17464290
[TBL] [Abstract][Full Text] [Related]
28. Dual inactivation of RB and p53 pathways in RAS-induced melanomas.
Bardeesy N; Bastian BC; Hezel A; Pinkel D; DePinho RA; Chin L
Mol Cell Biol; 2001 Mar; 21(6):2144-53. PubMed ID: 11238948
[TBL] [Abstract][Full Text] [Related]
29. Regulation of ATM/p53-dependent suppression of myc-induced lymphomas by Wip1 phosphatase.
Shreeram S; Hee WK; Demidov ON; Kek C; Yamaguchi H; Fornace AJ; Anderson CW; Appella E; Bulavin DV
J Exp Med; 2006 Dec; 203(13):2793-9. PubMed ID: 17158963
[TBL] [Abstract][Full Text] [Related]
30. A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis.
Berg T; Thoene S; Yap D; Wee T; Schoeler N; Rosten P; Lim E; Bilenky M; Mungall AJ; Oellerich T; Lee S; Lai CK; Umlandt P; Salmi A; Chang H; Yue L; Lai D; Cheng SW; Morin RD; Hirst M; Serve H; Marra MA; Morin GB; Gascoyne RD; Aparicio SA; Humphries RK
Blood; 2014 Jun; 123(25):3914-24. PubMed ID: 24802772
[TBL] [Abstract][Full Text] [Related]
31. Bptf determines oncogenic addiction in aggressive B-cell lymphomas.
Richart L; Felipe I; Delgado P; Andrés MP; Prieto J; Pozo ND; García JF; Piris MA; Ramiro A; Real FX
Oncogene; 2020 Jun; 39(25):4884-4895. PubMed ID: 32451433
[TBL] [Abstract][Full Text] [Related]
32. Pre-germinal center origin for mature mouse B cell lymphomas: a major discrepancy with human mature lymphomas.
Saintamand A; Garot A; Saad F; Moulinas R; Denizot Y
Cell Cycle; 2015; 14(22):3656-8. PubMed ID: 26654599
[No Abstract] [Full Text] [Related]
33. Transgenic N-myc mouse model for indolent B cell lymphoma: tumor characterization and analysis of genetic alterations in spontaneous and retrovirally accelerated tumors.
Sheppard RD; Samant SA; Rosenberg M; Silver LM; Cole MD
Oncogene; 1998 Oct; 17(16):2073-85. PubMed ID: 9798678
[TBL] [Abstract][Full Text] [Related]
34. MYC selects against reduced BCL2A1/A1 protein expression during B cell lymphomagenesis.
Sochalska M; Schuler F; Weiss JG; Prchal-Murphy M; Sexl V; Villunger A
Oncogene; 2017 Apr; 36(15):2066-2073. PubMed ID: 27694901
[TBL] [Abstract][Full Text] [Related]
35. Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation.
Nilsson JA; Keller UB; Baudino TA; Yang C; Norton S; Old JA; Nilsson LM; Neale G; Kramer DL; Porter CW; Cleveland JL
Cancer Cell; 2005 May; 7(5):433-44. PubMed ID: 15894264
[TBL] [Abstract][Full Text] [Related]
36. The role of p21(waf1/cip1) and p27(Kip1) in HDACi-mediated tumor cell death and cell cycle arrest in the Eμ-myc model of B-cell lymphoma.
Newbold A; Salmon JM; Martin BP; Stanley K; Johnstone RW
Oncogene; 2014 Nov; 33(47):5415-23. PubMed ID: 24292681
[TBL] [Abstract][Full Text] [Related]
37. Eμ-TCL1xMyc: A Novel Mouse Model for Concurrent CLL and B-Cell Lymphoma.
Lucas F; Rogers KA; Harrington BK; Pan A; Yu L; Breitbach J; Bundschuh R; Goettl VM; Hing ZA; Kanga P; Mantel R; Sampath D; Smith LL; Wasmuth R; White DK; Yan P; Byrd JC; Lapalombella R; Woyach JA
Clin Cancer Res; 2019 Oct; 25(20):6260-6273. PubMed ID: 31296529
[TBL] [Abstract][Full Text] [Related]
38. Development and survival of MYC-driven lymphomas require the MYC antagonist MNT to curb MYC-induced apoptosis.
Nguyen HV; Vandenberg CJ; Ng AP; Robati MR; Anstee NS; Rimes J; Hawkins ED; Cory S
Blood; 2020 Mar; 135(13):1019-1031. PubMed ID: 31978211
[TBL] [Abstract][Full Text] [Related]
39. Elevated Mdm2 expression induces chromosomal instability and confers a survival and growth advantage to B cells.
Wang P; Lushnikova T; Odvody J; Greiner TC; Jones SN; Eischen CM
Oncogene; 2008 Mar; 27(11):1590-8. PubMed ID: 17828300
[TBL] [Abstract][Full Text] [Related]
40. MYC-associated and double-hit lymphomas: a review of pathobiology, prognosis, and therapeutic approaches.
Petrich AM; Nabhan C; Smith SM
Cancer; 2014 Dec; 120(24):3884-95. PubMed ID: 25060588
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]